

## Review Article

# A brief history of antidepressant drug development: from tricyclics to beyond ketamine

Pereira VS, Hiroaki-Sato VA. A brief history of antidepressant drug development: from tricyclics to beyond ketamine.

**Objective:** Although monoaminergic-targeted drugs have prompted great advances in the development of treatments for depression, the need for new options persists, since these drugs still have a delayed clinical effect and most patients do not respond properly to them. Recently, the observation of the antidepressant effects of ketamine brought on a new wave of studies regarding the comprehension of the neurobiology of depression and the development of new and more effective antidepressant drugs.

**Methods:** Thus, in this paper, we present a historical review of the development of monoaminergic antidepressant drugs and the role of ketamine as the introductory agent of a new era in the research of the neurobiology of depression.

**Results:** Firstly, we review how the pharmacological treatment for major depression started, and we point out the main drugs discovered, the researchers involved, and how the studies developed have contributed to the understanding of the neurobiology of depression. Secondly, the major problems regarding the clinical efficacy and acceptance of these drugs are discussed, and the introduction of the glutamatergic system as a target for antidepressant drugs is presented. Finally, we review how ketamine revealed itself as an exciting option towards obtaining pharmacological agents to treat depression, through the understanding of biological markers.

**Discussion:** Ketamine contributed to confirm that different targets of the glutamatergic system and neurotrophic pathways are strictly related to the neurobiology of depression. There are several antidepressant drugs based on ketamine's mechanism of action already in the pipeline, and glutamatergic-targeted antidepressants may be on the market in the near future.

**Vitor Silva Pereira<sup>1</sup>, Vinícius Antonio Hiroaki-Sato<sup>2</sup>**

<sup>1</sup>Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark; and <sup>2</sup>Department of Pharmacology, Biological Section Building, Federal University of Paraná, Curitiba, Paraná, Brazil

Keywords: AMPA receptors; antidepressant drugs; brain-derived neurotrophic factor; ketamine; *N*-methyl-D-aspartate receptors

Vitor Silva Pereira, Postdoctoral Research Fellow Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Skovagervej 2, 8240 Risskov, Denmark.  
Tel: +45 4268 2713;  
E-mail: vitor.silvapereira@gmail.com

Accepted for publication November 14, 2017

First published online February 1, 2018

### Summations

- This review summarises the main facts of the history of antidepressant drug research and how ketamine revolutionized the search for new antidepressants.
- The reviewed evidence shows the main problems in the development of antidepressant drugs and the stagnation of the development of these drugs at the end of the 20th century.
- The main evidence of the antidepressant effects of ketamine, the new biological targets that ketamine helped identify and the drugs that were developed based on ketamine's mechanism of action are presented to show ketamine's relevance in the field.

### Considerations

- The review is based on the most relevant publications regarding the history of antidepressant drugs and on the relevant data demonstrating the antidepressant effects of ketamine.
- This review does not aim to include all literature regarding the behavioural effects of ketamine or *N*-methyl-D-aspartate (NMDA) antagonists. All articles were selected based on their relevance to the field of antidepressant research.

### Introduction

Major depression is a serious and debilitating disorder that can ultimately lead to suicide (1,2). The number of individuals affected by depression increased by 18.4% from 2005 to 2015, and more than 300 million individuals are estimated to suffer from depression at present (1). Furthermore, the World Health Organization indicates that depression is the leading cause of disability (1). Therefore, it is evident that appropriate and effective treatments for this disorder are necessary.

The pharmacological treatment for major depression is mostly based on drugs targeting the monoaminergic system (2,3). When they were developed, these drugs initiated a significant evolution for the treatment of mood disorders; but as depression becomes a growing health problem, these drugs do not follow the same pace regarding efficacy and acceptance (2,3). Consequently, the need and pressure for the development of new antidepressant drugs with improved efficacy is increasing.

The most promising solution for this challenge emerged at the beginning of the 21st century, when the fast and long-lasting antidepressant effects of the glutamatergic agent, ketamine, were shown for the first time (4). A great body of evidence has been built, showing the potential of glutamatergic drugs, like ketamine, as new and more effective antidepressant drugs (5–7).

Thus, in the present paper, we will review the history of the development of antidepressant drugs to show how and why monoaminergic antidepressants do not fulfil their treatment objectives. Furthermore, we will discuss how ketamine made history in the development of antidepressants, and how it is significantly improving this field. In order to do so, we review the main aspects of ketamine's mechanism of action and the drugs developed based on such a mechanism.

### The development of classical antidepressant drugs

The dawn of modern psychopharmacology and the first antidepressants

Until the late 1930s, there were no really effective treatments for depressive disorders. Many attempts were made, but they were almost all complete failures.

For example, some clinicians found partial relief of symptoms such as distress and agitation in depressive patients by using *tinctura opii*, first prescribed by Emil Kraepelin at the end of 19th century. Unfortunately, this had no effect on the depressed mood *per se* or suicidal tendencies (8,9). However, in the 1930s, the first treatments for catatonia, a type of schizophrenia, were discovered (10). These findings and the discovery that the experimental administration of psychogenic agents could induce catatonia (8) were a landmark for the emerging of biological psychiatry.

In parallel to these discoveries, Ernest Forneau and Daniel Bovet studied the structure of histamine aiming to find an antagonist since it had been confirmed that histamine was the causative agent in allergic response; in 1937, the first antihistaminic was synthesised (11). During the following years, several researchers worked to synthesise and study the link between the structure and activity of several antihistamines. Around 1950, this relationship was well established and contributed to the discovery of almost all antidepressants and antipsychotics (12) [for more structure-related information, see Domino (12)].

Shortly after World War II, P. Charpentier and his colleagues at Rhône Poulenc in France synthesised and tested a series of phenothiazine amines, which pharmacologists D. Bovet, B. Halpern and R. Ducrot found to have significant and long-lasting antihistaminic properties (12). One of the most potent phenothiazine amines was promethazine. The therapeutic and commercial success of promethazine as a sedative and possible antipsychotic prompted the synthesis of many modified phenothiazines for their potential central nervous system (CNS) effects (12). Finally, the first antipsychotic, chlorpromazine, was synthesised when chlorine was added to the promethazine structure (12), forming the basis of the development of the first antidepressants.

The therapeutic and commercial success of *N*-aminoalkylphenothiazines such as promethazine, promazine and chlorpromazine, motivated an enormous effort in the molecular modification of the polycyclic phenothiazine ring structure and its *N*-aminoalkyl side chain (12). In 1945, Häfliger and Schinder, replaced the Sulphur bridge of the phenothiazine ring of promethazine with an ethylene bridge to synthesise G22355, a weak antihistamine

and mild anticholinergic with sedative properties, in normal human volunteers (12). Since the chemical structure was similar to the one of chlorpromazine, it was given to Roland Kuhn in Germany to test its antipsychotic properties. The substance was ineffective in schizophrenia, but Kuhn recognised some of its potential antidepressant properties (13,14). During the World Psychiatric Association Meeting in Zurich, in 1957, the first public report on the antidepressant effects of G22355, later named imipramine, was written by Kuhn (9). Kuhn discovered that among patients with different psychiatric disorders treated with imipramine, those with endogenous depression and mental and motor retardation showed a remarkable improvement after ~1 to 6 weeks of daily therapy (12). Thus, the first clinically useful tricyclic antidepressant (TCA) was discovered, and by the end of the same year of its first publication, it was released for clinical use in Switzerland under the brand name Tofranil (12,15).

Parallel to the study of imipramine, the history of iproniazid started at the Sea View Hospital on Staten Island (New York). In 1952, Irving J. Selikoff and Edward Robitzek carried out studies on the clinical effects of iproniazid. They observed that this drug greatly stimulated the CNS, which was initially interpreted as a side effect. At that time, many studies on the antidepressant effects of antitubercular hydrazide agents were performed (16,17). It was during one of these studies that the term 'antidepressant' was probably coined by Max Lurie, a psychiatrist with a private practice in Cincinnati, to refer to the effect of iproniazid in depressed patients (18).

In 1957, psychiatrists Nathan S. Kline, Harry P. Loomer and John C. Saunders from Rockland State Hospital (Orangeburg, NY) were the first to present results assessing the efficacy of iproniazid in non-tuberculosis depressed patients (9,17). Just 1 year after this first presentation at the Syracuse meeting (April, 1957), more than 400 000 patients affected by depression had been treated with the first class of antidepressants to reach the market (19).

This a new set of drugs was defined and called antidepressants, which were pioneered by iproniazid [later classified as a monoamine oxidase inhibitor (MAOI)] and imipramine (later classified as a TCA).

### The rise and reign of Prozac

The discovery of the mechanisms of action of iproniazid and imipramine was of fundamental importance to the formulation of the initial aetiological theories of depressive disorder.

By the time the antidepressant effects of iproniazid we published, it was already known that it inhibited the enzyme monoamine oxidase (MAO). In 1952, the

team led by Ernst Albert Zeller at Northwestern University Medical School (Chicago, IL) observed for the first time that iproniazid (and not isoniazid) was capable of inhibiting MAO (20). In 1959, Sigg observed the potentiation of noradrenaline (NA) by imipramine (21), and, in 1961, Brodie and his team at the National Institutes of Mental Health (NIMH) introduced the reserpine syndrome as a model for depression. At the same time, Axelrod and his co-workers at NIMH discovered the reuptake blocking of noradrenaline by TCAs (22). Finally, in 1965, Schildkraut, Bunney and Davis suggested the catecholamine hypothesis of depression, postulating that depression was caused by low levels of epinephrine and norepinephrine in the CNS (23,24).

At the same time, other findings contributed to the introduction of a new protagonist, 5-hydroxytryptamine (5-HT or serotonin) in the search for the molecule behind depression. In addition to the noradrenergic system (25), reserpine, imipramine and iproniazid also affect the 5-HT system, and 5-HT neurotransmission seems to have an essential role in animal sedation (26). Additionally, the therapeutic effect of MAOIs and TCAs was later shown to be blocked by the administration of 5-HT synthesis inhibitors (27,28). Therefore, Copen (1967) proposed that 5-HT was a more important neurotransmitter in depression than NA, based on experiments on animals in which the administration of tryptophan, the precursor of serotonin, boosted the antidepressant-like effects of MAOIs (17,25,29). In 1969, the discovery that TCAs could block the reuptake of serotonin in presynaptic neurons allowed Lapin and Oxenkrug to postulate the serotonergic theory of depression, which was based on a deficit of serotonin at an inter-synaptic level in certain brain regions (30).

Even though there was initially no consensus whether the antidepressant-like effects of iproniazid resulted from MAO inhibition or not, several other MAOIs were introduced on the market after 1957 (31). Despite being one of the only alternatives for treating depression, the hepatotoxicity caused by drugs such as iproniazid and pheniprazine and the hypertensive crisis induced by the inhibition of peripheral MAO caused this class of drugs to become obsolete (20). In 1961, other tricyclics such as amitriptyline were synthesised by modifying the structure of imipramine (32), and the desmethyl derivative of imipramine, desipramine, was introduced in 1964 as the active metabolite of imipramine (33). In 1963, nortriptyline was approved in Great Britain, followed by trimipramine, protriptyline (1966), iprindole (1967), dothiepin and doxepin (1969) (34). Despite being less tolerated due to a higher probability of adverse effects than the selective serotonin reuptake

inhibitors (SSRI) that were to come later, TCAs are currently still among the most frequently prescribed drugs in the world (35,36).

For the first time in the history of psychopharmacology, the postulation of the monoaminergic theories of depression led to a new search methodology for new therapeutic drugs. Having fluoxetine as their prototype, the SSRIs were the first class of drugs developed after a planned strategy and with a methodology of rational design, aiming for drugs which act in a specific site (the protein responsible for the serotonin reuptake, 5-HT). This strategy made it possible to avoid unspecific actions and culminated in more selective drugs and, consequently, decreased the frequency and probability of undesired effects (17).

At first, the fluoxetine idealisation was based on the prominent serotonin theory of depression which was in evidence in the 1960s, backed up by the literature at the time. Subsequently, the pharmaceutical company Eli Lilly created a 'serotonin-depression study team', composed by the researchers Fuller, WongMolloy and Rathbun (17) whose search for molecules that could selectively inhibit the reuptake of serotonin aimed to minimise collateral effects, such as cardiovascular toxicity and anticholinergic properties of the TCAs. Therefore, they started, once more, with basic antihistamines and synthesised dozens of compounds by modifying phenoxyphenyl-propylamines (12). On July 24th, 1972, LY-110140 (fluoxetine hydrochloride) was designated the most powerful and selective inhibitor of serotonin uptake among all the compounds developed (37). In December 1987 after a series of clinical studies confirming that fluoxetine was as effective as the TCAs, along with the advantage of fewer adverse effects (38,39), the Food and Drug Administration (FDA) approved its clinical use, allowing Prozac to be released onto the market (17).

Prozac had the fastest growth in use in the history of psychotropic drugs. By 1990, it was the most widely prescribed drug in North America and, in 1994, it was the second biggest selling drug in the world (17). The increasing need for a drug to treat the fearsome medical condition: Major depression, which strongly stimulated the rise and establishment of fluoxetine and the subsequent SSRIs to unprecedented levels. In contrast, in 1982, the first SSRI, zimelidine, was marketed in Sweden but had to be withdrawn from the market due to serious adverse effects related to its use, namely Guillain-Barré Syndrome (40). However, four other SSRIs were released in the market alongside fluoxetine; that is, citalopram (Lundbeck, 1989 in Denmark), fluvoxamine (Solvay, 1983 in Switzerland), paroxetine (AS Ferrosan, Novo Nordisk, 1991 in Sweden) and sertraline (Pfizer, 1990 in UK) (17).

The number of visits to general practitioners due to depression increased from 10.9 million in 1988 to 20.43 million in 1994 (41), and the prescriptions for all antidepressants rose from 40 million in 1988 to 120 million just one decade later (42). Even though it is highly debatable whether the rise of Prozac was only a psychotherapeutic phenomenon or placebo features were involved, the fact is that it happened in such an unprecedented manner that it is referred to as the 'Prozac Boom' (43).

The dusk of antidepressants in the late 20th century

Even though SSRIs dominated the antidepressant market in the 1990s, not all expectations about these drugs were fulfilled. Although the adverse effects of the TCAs were worse, the SSRIs still caused side effects; for example, fluoxetine and SSRIs can interfere with sex and appetite, cause vomiting and nausea, irritability, anxiety, insomnia and headaches (2). To a lesser extent, it can also induce parkinsonism, agitation, spasms and tics (2).

In an effort to reduce the adverse effects of the first SSRIs, other antidepressants emerged during the 1990s, such as venlafaxine (a selective noradrenaline and serotonin reuptake inhibitor), reboxetine (a selective noradrenaline reuptake inhibitor), nefazodone (selective serotonin-5HT<sub>2A</sub> receptor blocker, a weak 5-HT reuptake inhibitor, structurally and pharmacologically related to trazodone) and mirtazapine ( $\alpha$ <sub>2</sub>-adrenoreceptor blocker, pharmacologically related to mianserin) (2,31). In the same way as the SSRIs, these new agents elicited different tolerance rates and side effects but offered no improvement in efficacy, therefore not being a huge advancement (2). Figure 1 shows a generic representation of a monoaminergic neurotransmission with the main targets of classical antidepressants and the year that the main antidepressant drugs reached the market.

The SSRIs have not succeeded in solving several of the previous issues related to the use of antidepressants. For example, it still takes from 2 to 4 weeks for these drugs to exert an antidepressant effect (3). This delay of clinical effect has always raised questions about the veracity of the monoaminergic hypothesis of depression, since studies show an acute increase in monoamines in the synaptic cleft (noradrenaline or serotonin) right after the treatment (44). In addition, the decrease of serotonin levels in the brain caused by the acute depletion of tryptophan, serotonin's precursor, does not induce a depressive-like behaviour in healthy humans (45–47). This evidence shows that much more than monoaminergic neurotransmitter levels should be targeted in the brain of depressed individuals.

In 1937, Hohman published an article with a retrospective study of the outcome of depressed




Fig. 1. General representation of a monoaminergic neurotransmission. Black arrows show the general synthesis process of monoamines until they are stored into the vesicles. Purple dots represent the monoamines. Pink arrows show the main neuronal targets of monoamines, which can be postsynaptic ionotropic and metabotropic receptors, as they can also act on presynaptic metabotropic receptors. Purple arrows show the reuptake mechanism of monoamines that leads them to be degraded by monoamine oxidase (MAO). Red arrows show the main targets of the classical monoaminergic antidepressants. Green boxes show the main drugs and classes of antidepressants related to each target and the year that each drug reached the market.

patients. After 7 years of observation, only one in three recovered within a year, whereas one out of four recovered within 2 years, and about 15% remained chronic and did not recover at all (48). At that time, however, no effective treatments for depression existed. Even nowadays, studies on the remission rates of depression after treatment show conflicting numbers. According to some authors, this number ranges from 30% (49) to 45% of the patients (50), whereas the literature comprises many different assumptions. One of the reasons for these differences stems from divergences in the samples analysed; but in general, a significant percentage of these patients never achieve full remission.

Some authors believed that the treatments available on the market only reduced the frequency, duration and severity of symptoms as well as the mortality by suicide (9). In fact, in the last decade, the non-effectiveness of antidepressants has been subject of considerable debate. However, the World Health Organization's compiled data show that both TCAs and SSRIs are significantly more effective than placebo (51).

In this scenario, the discovery of a new effect of an old drug emerges (Fig. 2).

### Ketamine: turning tables on antidepressant research

The history of ketamine

In 1956, an anaesthetic compound called phencyclidine was synthesised at Parke, Davis & Co. laboratories in Detroit, MI, USA (52). Animal studies showed that this drug had remarkable anaesthetic effects and could cause behavioural alterations. Thus, after toxicity studies, it was approved for use in humans (53). However, clinical studies showed that phencyclidine was not ideal for human anaesthesia since it might cause long-lasting emergence delirium and lead to something similar to a schizophrenic syndrome (54). Given that this drug had interesting anaesthetic effects, Parke, Davis & Co. decided to search for a phencyclidine derivative with a shorter period of action to avoid the long-lasting behavioural side effects (53). One of the synthesised compounds, CI-581, successfully underwent pre-clinical studies and was approved for human studies, which led to Parke, Davis & Co. contacting Dr. Edward F. Domino to lead such clinical studies. In 1964, the first human experiment with CI-581, later named as ketamine, was conducted on prisoners from the Jackson Prison, Michigan, USA. The studies

## Antidepressant Development




Fig. 2. Main facts on antidepressant drug development from 1930 until now. ADP, antidepressant; MDD, major depressive disorder; MAOI, monoamine oxidase inhibitors; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants; WW2, World War 2.

conducted by Dr. Domino produced notable results accompanied by fewer side effects (53). However, the behavioural side effects of ketamine were still considerable and in order to get the FDA approval for clinical use, they decided to call it a 'dissociative anaesthetic', which proved to be a successful measure. Interestingly, the term 'dissociative anaesthetic' came from Dr. Domino's wife during a conversation as described, among other facts about ketamine development, in his insightful review (53).

The history of ketamine up to now can be divided into five different periods according to the number of published articles after its synthesis and the different

phases in the studies on its effects. In the first published clinical study on ketamine from 1965, Edward F. Domino et al. describe the clinical effects of a dissociative anaesthetic called CI-581 (55). From 1965 to the end of 1969, fewer than 50 published studies corroborate the potential effects of ketamine as an anaesthetic agent for clinical use (56,57).

During the second period from 1970 to the end of 1974, the use of ketamine in different kinds of anaesthesia as well as its dissociative effects are confirmed and established (58–60). This period represents the beginning of extensive research and interest in ketamine, substantiated by more than 1000

studies published during these 5 years. The first and second period also mark the transition of ketamine from a street abuse drug to a scheduled and controlled drug after its approval by the FDA (53). The fact that it is still used as an abuse drug represents a main concern in using ketamine as an antidepressant agent (61,62).

During the third period from 1975 to 1989, 300–400 articles were produced a year, depicting the mechanisms of ketamine and its effects. In parallel, the glutamatergic system was also being characterised at the time, and the NMDA receptor was identified as one of the receptors of this neurotransmission system (63). Thus, the main site of action of ketamine was described, since ketamine blocks the effects of the glutamatergic mediator *glutamate* on the NMDA receptor (NMDAR) by physically blocking the receptor channel (64,65). However, it is important to highlight that ketamine is not selective only to the NMDAR; to a lesser extent, it can also on over other targets such as opioid receptors, sigma receptors and by inhibiting the reuptake of monoamines (66–68).

During the fourth period, dating from 1990 to 1999, around 470–600 published articles related to ketamine were produced a year. The interest in the glutamatergic system and its importance in the control of behavioural responses to stress exposition was also growing. Consequently, ketamine was under the spotlight since its main target was now known. In 1990, studies showed that the injection of NMDA modulators, like MK-801 and ACPC, was capable of inducing antidepressant-like effects in mice exposed to the forced swim test (69). A few years later, further evidence showed that stress exposition would increase glutamate release in key areas for behaviour control in the brain as elucidated by Moghaddam et al. in different works (70–72). Corroborating such findings, Nowak et al. and Skolnick et al. demonstrated that treatment with classical monoaminergic antidepressant drugs induced adaptive changes on NMDARs and in brain areas important to mood control (73,74). Therefore, it was during the final decade of the 20th century that researchers laid the foundations for the realisation of the involvement of glutamatergic mechanism in the neurobiology of depression.

Finally, the fifth period comprised an explosion of interest and research in ketamine and its behavioural effects. In the beginning of 2000, Biological Psychiatry published a groundbreaking study by Berman RM et al. who for the first time showed that it was possible to obtain fast and lasting antidepressant effects; that is, within hours and up to 3 days (4). Moreover, such effects could be obtained with a reduced dose of an already widely used drug:

Ketamine (4). This came at a time of intense pressure for the development of antidepressants, since depression was affecting an increasing number of individuals and no better treatment options had been discovered. The year 2000 marked the shift conducted by ketamine in the history of the development of antidepressant drugs, since a new treatment to the 'plague of the 21st Century', that is major depression, was found.

Old drug, new insights on depression research


It took more than 40 years from the initial synthesis of ketamine until its antidepressant effects were elucidated by Berman et al. in 2000. These effects were corroborated by several other clinical and pre-clinical studies (7,75,76). The trials executed by Dr. Carlos Zarate Junior's research group are the major clinical evidence supporting how ketamine elicits fast and long-lasting effects, as well as they support the mechanisms through which it can be effective in treatment-resistant depression (77–79). In a great variety of animal models, several pre-clinical studies have shown that ketamine and other glutamatergic modulators can promote antidepressant-like effects as they also help to identify the mechanisms through which such drugs induce their behavioural effects (80–83). A quick search in the online database *clinicaltrials.gov* (last consulted on 21/09/2017) shows more than 100 clinical trials involving ketamine and major depression exist; 44 of studies are recruiting or active, thus reinforcing the impact of ketamine on antidepressant research.

### Depicting the mechanism of ketamine: more than NMDA antagonism

The mechanism responsible for ketamine's antidepressant effects goes beyond the antagonism of glutamate on the NMDAR. It involves a multistep and complex cascade of events relying on different molecular targets. We will now review the main mediators and the most important evidence supporting the proposed mechanism of action of ketamine as an antidepressant.

The antidepressant mechanism of action of ketamine

The proposed mechanism of action for ketamine can be divided into two chains of events. The first chain starts with the antagonism of the NMDAR, which is subsequently followed by three main steps: the reduction of nitric oxide (NO) production, the increase of glutamate release and the increased activation of AMPA receptors (AMPA). Figure 3 shows the proposed mechanism of action of ketamine



*Fig. 3.* The proposed mechanism of action of ketamine regarding fast and long-lasting antidepressant effects. *Red arrows* show the beginning of ketamine’s action by blocking *N*-methyl-D-aspartate receptors (NMDARs) on postsynaptic glutamatergic terminals and on gabaergic neurons, which leads to two main simultaneous effects. *The black arrow* shows that the blockade of NMDAR on postsynaptic glutamatergic terminals leads to reduced production of nitric oxide (NO). *The orange arrow* shows the reduced release of GABA by gabaergic neurons, which leads to reduced inhibition of presynaptic glutamatergic terminals and increased release of glutamate. The increased release of glutamate (*purple dots*) leads to an augmented drive of activation through AMPA receptors (AMPA) as shown by *purple arrows*. *Green arrows* show that the activation of AMPAR can lead to (1) direct stimulation of the PI3K–AKT–mechanistic target of rapamycin (mTOR) pathway or (2) indirect activation of the same pathway through the activation of L-type voltage dependent calcium channels (L-VDCC), which increases the release of brain-derived neurotrophic factor (BDNF) that can then activate *tyrosine receptor kinase B* (TrkB) receptors. *Dark grey arrows* show the reduction of the *glycogen synthase kinase-3β* (GSK-3β) effects over mTOR and AMPAR. *Light grey arrows* show the recycling of glutamate occurring through astrocytes, which release glutamine that will be transported to the presynaptic terminal by excitatory amino acid transporters (EAAT). *Blue arrows* show the synthesis of glutamate from glutamine through glutaminase action until the storage into the vesicles.

that leads to fast and long-lasting antidepressant effects.

The production of NO can be induced by several neurotransmission systems like the cholinergic (84,85), serotonergic (86) and purinergic systems (87,88). However, NMDAR activation is the main trigger for NO production (89). After NMDAR activation, an increase in calcium influx is observed, activating neuronal responses as it also leads to the formation of the  $Ca^{+2}$ -calmodulin complex, which, in turn, activates neuronal NO synthase to produce NO (90). NO is an atypical neurotransmitter that plays an important role in the neurobiology of

depression (91). Various reports show that NO can modulate different processes in the brain as it is capable of modulating the release of neurotransmitters and affect neuronal plasticity (90,92). Many pre-clinical studies regarding depression have demonstrated that NO inhibitors induce antidepressant-like effects in animal models such as the forced swim test (93–95) and chronic mild stress (96,97). Nonetheless, none of these drugs is available for clinical use so far. Confirming the link between ketamine effects and NO, two different studies have shown that the pre-treatment with the NO precursor L-arginine can block the effects of ketamine in rats exposed to the forced



swim test (98,99). Furthermore, the effects of a sub effective dose of ketamine were potentiated by a sub effective dose of the NO inhibitor L-NAME (98). In addition, the effects of ketamine also relate to a reduction of the NO pathway activity in the hippocampus of rats (98,99). Therefore, it seems that the reduction in NO activity in the brain is an important feature of ketamine's antidepressant effect.

The second step, the increase of glutamate release, is proposed to happen through NMDAR blockade on GABAergic interneurons. This event would cause an inhibition of the GABAergic modulatory action over glutamatergic neurons, thus leading to a disinhibited state of the glutamatergic neurons (100). Indeed, evidence shows that a low dose of ketamine increases the release of glutamate in the prefrontal cortex of rats, which is not seen with high doses of ketamine (71). Therefore, a key action of ketamine seems to be the reduction of the NMDA drive of the glutamatergic neurotransmission and the increase of the amount of glutamate available to act on other targets such as the glutamatergic AMPAR (7), which should be kept in mind for further discussion.

The third main action responsible for the effects of ketamine on depression is the increase of the activation of AMPAR. Different pieces of work show that pre-treatment with AMPAR antagonists can block the behavioural effects of ketamine and other NMDAR antagonists (80,83,101,102). Furthermore, reports show that AMPAR potentiators can induce antidepressant-like effects (103,104). Interestingly, monoaminergic antidepressants seem to be able to facilitate the glutamatergic transmission through AMPAR while decreasing NMDAR driven transmission (105,106). Thus, increasing the AMPA drive of the glutamatergic system seems necessary to produce the antidepressant effects of ketamine.

The second chain starts after the increased activation of the AMPAR, which is followed by a set of events and culminates on the activation of the *mechanistic target of rapamycin* (mTOR). Such events seem to occur through the activation of *L-type voltage dependent calcium channels* (L-VDC), leading to increased release of brain-derived neurotrophic factor (BDNF), which in turn, activates the *tyrosine receptor kinase B* (TrkB)–Akt–mTOR pathway. Data obtained from *in vitro* experiments show that the activation of AMPAR increases the release of BDNF dependently of L-VDC (107,108), and recent evidence shows that the systemic injection of L-VDC inhibitors can block the antidepressant-like effects of ketamine (108). However, further studies are necessary to corroborate this evidence.

The interplay between the antidepressant effects of NMDAR antagonists and the BDNF pathway has been tested through different protocols. The

antidepressant-like effects of ketamine and MK-801 in mice showed to be dependent on a fast increase of BDNF synthesis (81). Nonetheless, genetically modified animals that exhibit lower BDNF levels do not respond to ketamine when exposed to the forced swim test (109). Corroborating such evidence, the infusion of an anti-BDNF antibody into the prefrontal cortex was shown to be capable of blocking the effects of ketamine (108). Interestingly, ketamine abusers present increased serum levels of BDNF (110).

After BDNF activation of TrkB, there is another important downstream molecular mediator of ketamine's antidepressant effect; mTOR, a key protein involved in the control of cell growth and proliferation (80,111). Initially, the NMDAR antagonist, MK-801, was shown to be capable of increasing the synthesis of synaptic proteins into the prefrontal cortex of rats in a way dependent on mTOR activation (112). Posteriorly, it was demonstrated that the antidepressant-like effects of different NMDA antagonists as ketamine, Ro 25-6981 and LY 235959 are blocked by mTOR inhibition in the prefrontal cortex of rats exposed to the forced swim test (80,82,83). Ketamine was found to increase protein synthesis and spine density in the prefrontal cortex of rats, which could be blocked by the mTOR inhibitor rapamycin (80). Thus, there is strong evidence supporting the idea that the antidepressant effects of ketamine depend on the BDNF–TrkB–mTOR pathway.

It is important to highlight that AMPARs might lead to mTOR activation through a more direct pathway, independently of BDNF and TrkB. *In vitro* data show that AMPAR from striatal neurons can influence neuronal plasticity and gene expression through the activation of MEK/ERK and *phosphatidylinositol 3-kinase* (PI3K)/AKT pathways, depending on  $Ca^{+2}$  influx (113,114). Both MEK/ERK and PI3K/AKT pathways are the main mediators able to activate mTOR (111,115). Furthermore, it has been reported that the fast antidepressant-like effects of ketamine and an AMPAR potentiator, LY 451646, induced an antidepressant-like effect without increasing the level of BDNF or the phosphorylation of TrkB into the hippocampus of mice (104). Therefore, future studies may help clarify the role of such mechanisms on the antidepressant effects of fast-acting drugs.

One final mediator to be mentioned is *glycogen synthase kinase 3* (GSK-3), which is a kinase involved in several cellular processes like cell signalling, proliferation, plasticity and apoptosis (116), as it can also act by inhibiting mTOR (117). Evidence shows that ketamine can inhibit GSK-3 and that its antidepressant-like effects are dependent on this inhibition (118). Furthermore, the same study demonstrated that a high dose of lithium, a mood

stabiliser inhibiting GSK-3, could induce an antidepressant-like effect in a similar way to ketamine (118). Similarly, Liu et al. and Chiu et al. showed that lithium and a specific GSK-3 inhibitor potentiated the synaptogenic and the antidepressant-like effects of an ineffective dose of ketamine (119,120). Most recently, researchers showed that ketamine's inhibition of GSK-3 reduces the internalisation of AMPAR, thus reinforcing the effects of increasing the glutamatergic drive through AMPA transmission (118,121). However, the isolated use of a specific GSK-3 inhibitor failed to induce any antidepressant-like effect on mice exposed to chronic mild stress (122), which indicates that similar net effects as the ones promoted by ketamine are necessary to reproduce similar antidepressant actions. The role of GSK-3 as a target for new antidepressant drugs is promising, but more studies are necessary to understand its role on behavioural control mechanisms.

Regarding the aforementioned data, ketamine stimulated the research field of antidepressant drugs by highlighting the role of important biological markers involved in a fast and long-lasting antidepressant effect. At present, most of the ongoing work on new antidepressant treatments is investigating the manner in which the potential drugs interact with AMPAR, BDNF, TrkB, mTOR and most recently GSK-3.

### State of the art

Ketamine brought new ideas to the research of the neurobiology of depression, but it is not a wonder drug. Its psychotomimetic effects and abuse potential are difficult to overlook, thus it is not suitable for wide clinical use (62,123). Furthermore, it is necessary to emphasise that more studies, with large-scale samples, long-term evaluation, repeated dosing, tolerance and safety assessment are needed to fill the gaps regarding our knowledge about the use of ketamine for depression. The scientific community has discussed these issues, since the off-label use of ketamine has been growing among depressed patients (124–126). Such practice is not recommended because important factors are still to be defined; like the most effective dose, treatment setting and an optimal administration pathway (124–126). It is plausible to consider that ketamine may never reach the market as an antidepressant, but it paved the way to the development of potential antidepressant drugs.

Ketamine brought science several steps closer to the development of new and improved antidepressant drugs by shedding light on several targets, which might provide agents without the same unfortunate side effects as ketamine. Thus, we will now discuss some of the most prominent drugs for depression treatment aiming targets evidenced by ketamine studies.

Besides ketamine, other NMDA antagonists are under consideration as new antidepressant drugs. Among these, the selective antagonists of the GluN2B subunit of the NMDAR deserve more attention. The compound Ro 25-6981 has induced anxiolytic and antidepressant-like effects in animal studies (80,127), and such effects seem to be unaccompanied by psychotomimetic effects (128). Another compound, CPP-101,606 (traxoprodil), induced antidepressant effects both in treatment-resistant individuals (129) and in animals (130), but clinical data showed that it causes cardiac adverse effects (129,131). Most recently, another agent, MK-0657, was introduced and shown to have improved the mood of treatment-resistant individuals without inducing dissociative symptoms (132). However, a phase-2 placebo-controlled trial (NCT02459236) did not reach the primary endpoint of improvement on the Hamilton Rating Scale for Depression with CERC-301 (former MK-0657) at doses of 12 and 20 mg/kg (131). A recent report indicates that GluN2B antagonists tested in non-human primates might induce transient cognitive impairment (133). Therefore, further investigations are necessary to confirm if these drugs can be applied for the open clinical treatment of depression.

Another interesting way to modulate the NMDAR is through the glycine site. Glycine acts as a co-agonist at the NMDAR by facilitating the receptor activation by glutamate (134,135). Thus, drugs blocking or reducing the action of glycine could induce interesting behavioural effects like those of the NMDAR antagonists. In 1990, Trullas and Skolnick were the first to show that the systemic injection of a partial agonist of glycine site, ACPC, was able to induce an antidepressant-like effect in mice exposed to the forced swim test or to the tail suspension test (69). Interestingly, recent studies have demonstrated that a glycine site modulator, Rapastinel (former Glyx-13), has interesting effects as a cognitive enhancer (136,137) as it also induces important pre-clinical and clinical antidepressant effects (138,139). Rapastinel has been shown to induce antidepressant-like effects in animals which like ketamine involve AMPAR and mTOR signalling, long-term changes in synaptic plasticity and are not followed by psychotomimetic effects (137,140–142). More importantly, Rapastinel has been a promising tool in clinical studies as it is in advanced phases of clinical trials and may represent the first fast-acting antidepressant drug to be approved for clinical use (142–145).

Recent evidence pointed out that the metabolites of ketamine could play an important role in the observed antidepressant effects. Initially, ketamine is metabolised to norketamine, which was thought to

be the main active product, since it is the only one able to induce anaesthesia like ketamine (146). However, current evidence also shows that norketamine can induce antidepressant-like effects (147). Additionally, it was demonstrated that the main ketamine metabolites are, in fact, the hidroxinorketamines (HNK) (78,148) and that some of these HNK could be involved in the long-lasting effects of ketamine (78,149). Zanos et al. (2016) demonstrated that the ketamine metabolite 2R,6R-HNK exerts an antidepressant-like effect in a series of animal models for antidepressant activity, and that it does not induce any psychotomimetic effect (149). Furthermore, they showed that the effects of 2R,6R-HNK involve (1) direct activation of AMPAR, (2) time dependent activation of the BDNF–mTOR pathway and (3) maintenance of synaptic potentiation (149). Therefore, the use of ketamine metabolites may represent a new tool for the development of the next generation of fast-acting antidepressant drugs.

Another pharmacological tool that may be useful for the development of new antidepressant drugs is the positive modulation of AMPAR. As seen previously, the enhancement of the glutamatergic AMPAR-driven transmission is an important part for the fast and long-lasting effects of NMDAR antagonists, such as ketamine. However, given pharmacological matters, the use of agonists is difficult, mainly because of potential tachyphylaxis, since receptor potentiators are normally partial agonists (62). Some AMPAR potentiators have shown promising antidepressant-like effects, as LY392098 (103,150) and LY 451646 (104). For instance, Org 26576 was tested in humans and presented interesting antidepressant effects (151,152), but it failed in phase-2 trials (145). Other AMPAR potentiators are under development or starting clinical trials (145,153); therefore, data presented in the future may confirm that these drugs will be useful for the treatment of depression.

### Concluding remarks

Ketamine can be considered one of the most important drugs synthesised in the 20th century given its clinical and social impact over the years. Nonetheless, it remains relevant in the 21st century, given its great influence on behavioural research and depression treatment. In fact, the beneficial effects of ketamine on behaviour are not new but they were not considered relevant when first noticed, as reported by Dr. Edward Domino (53). Luckily, such effects were not ignored in the studies developed later.

All the data reviewed in the present paper demonstrate the importance of ketamine not only by shedding light on more targets which could potentially treat depression, but also by further

elucidating the neurobiology of this disorder. Nevertheless, there are still many unanswered questions about the mechanism through which ketamine induces such remarkable antidepressant effects and how these mechanisms interact with other neurotransmission systems (62). Several ongoing studies will help clarify the impact of the glutamatergic modulation *per se* or its interaction with monoaminergic, nitrergic and inflammatory systems, as the role of plasticity shifts into the complex grid of behavioural control (62,68,154). Finally, ketamine has rescued the interest in new treatments for depression, which was decreasing by the end of 1990s. Therefore, in the near future, there is a great hope of having better pharmacological treatments for depression available.

### Acknowledgements

The authors thank CNPq (PDE – 203647/2014-9) for the funding provided. The authors also thank Fernanda Rodella, Karen J. Madsen and Maja C. Strand for proofreading the present paper. Authors' Contributions: V.S.P. designed the review and reviewed all information regarding ketamine. V.A.H.S. reviewed all the information regarding the history of antidepressants.

### Conflicts of Interest

None.

### References

1. ORGANIZATION WH. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017; License: CC BY-NC-SA 3.0 IGO.
2. MILLAN MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol Ther* 2006;**110**:135–370.
3. HINDMARCH I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. *Eur Psychiatry* 2002;**17**(Suppl. 3): 294–299.
4. BERMAN RM, CAPPIELLO A, ANAND A et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 2000;**47**:351–354.
5. ABDALLAH CG, ADAMS TG, KERMENDI B, ESTERLIS I, SANACORA G, KRYSAL JH. Ketamine's mechanism of action: a path to rapid-acting antidepressants. *Depress Anxiety* 2016;**33**:689–697.
6. ZARATE CA JR., MACHADO-VIEIRA R. Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. *Mol Psychiatry* 2017; **22**:324–327.
7. BROWNE CA, LUCKI I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. *Front Pharmacol* 2013;**4**:161.

8. BAN TA. Pharmacotherapy of mental illness – a historical analysis. *Prog Neuropsychopharmacol Biol Psychiatry* 2001;**25**:709–727.
9. LEHMANN HE. Historical evolution of antidepressant drugs. *International Network for the History of Neuropsychopharmacology*. 1986, 18.
10. LEHMANN HE, BAN TA. The history of the psychopharmacology of schizophrenia. *Can J Psychiatry* 1997;**42**:152–162.
11. COZANITIS DA. Daniel Bovet, Nobelist: muscle relaxants in anaesthesia: the role played by two neglected protagonists. *Wien Med Wochenschr* 2016;**166**:487–499.
12. DOMINO EF. History of modern psychopharmacology: a personal view with an emphasis on antidepressants. *Psychosom Med* 1999;**61**:591–598.
13. KUHN R. The treatment of depressive states with G 22355 (imipramine hydrochloride). *Am J Psychiatry* 1958;**115**:459–464.
14. AYD FJ, BLACKWELL B. Taylor Manor Hospital. Discoveries in biological psychiatry. Philadelphia: Lippincott, 1970; 254 pp.
15. BAN TA. In memory of three pioneers. *Int J Neuropsychopharmacol* 2006;**9**:475–477.
16. ZELLER EA, BARSKY J, FOUTS JR, KIRCHHEIMER WF, VANORDEN LS. Influence of isonicotinic acid hydrazide (Inh) and 1-isonicotinyl-2-isopropyl hydrazide (Iih) on bacterial and mammalian enzymes. *Experientia* 1952;**8**:349–350.
17. LOPEZ-MUNOZ F, ALAMO C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. *Curr Pharm Des* 2009;**15**:1563–1586.
18. SALZER HM, LURIE ML. Anxiety and depressive states treated with isonicotinic acid hydrazide (isoniazid). *AMA Arch Neurol Psychiatry* 1953;**70**:317–324.
19. LEWIS JG. Drug discovery; the evolution of modern medicines. *Postgraduate Med J* 1986;**62**:704.
20. LOPEZ-MUNOZ F, ALAMO C, JUCKEL G, ASSION HJ. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. *J Clin Psychopharmacol* 2007;**27**:555–559.
21. SIGG EB. Pharmacological studies with Tofranil. *Can Psychiatr Assoc J* 1959;**4**(Suppl.):75–85.
22. HERTING G, AXELROD J, WHITBY LG. Effect of drugs on the uptake and metabolism of H<sub>3</sub>-norepinephrine. *J Pharmacol Exp Ther* 1961;**134**:146–153.
23. SCHILDKRAUT JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. *Am J Psychiatry* 1965;**122**:509–522.
24. SCHILDKRAUT JJ, GORDON EK, DURELL J. Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. *J Psychiatr Res* 1965;**3**:213–228.
25. COPPEN A. The biochemistry of affective disorders. *Br J Psychiatry* 1967;**113**:1237–1264.
26. BRODIE BB, COMER MS, COSTA E, DLABAC A. The role of brain serotonin in the mechanism of the central action of reserpine. *J Pharmacol Exp Ther* 1966;**152**:340–349.
27. SHOPSIN B, FRIEDMAN E, GERSHON S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. *Arch Gen Psychiatry* 1976;**33**:811–819.
28. SHOPSIN B, GERSHON S, GOLDSTEIN M, FRIEDMAN E, WILK S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. *Psychopharmacol Commun* 1975;**1**:239–249.
29. COPPEN A, SHAW DM, FARRELL JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. *Lancet* 1963;**1**:79–81.
30. LAPIN IP, OXENKRUG GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. *Lancet* 1969;**1**:132–136.
31. BAN TA. Pharmacotherapy of depression: a historical analysis. *J Neural Transm (Vienna)* 2001;**108**:707–716.
32. KUHN R. The imipramine story. In: Ayd FJ editor *Discoveries in biological psychiatry*. Philadelphia: JB Lippincott, 1970; p. 205–217.
33. BRODIE BB, BICKEL MH, SULSER F. Desmethylimipramine, a new type of antidepressant drug. *Med Exp Int J Exp Med* 1961;**5**:454–458.
34. FANGMANN P, ASSION HJ, JUCKEL G, GONZALEZ CA, LOPEZ-MUNOZ F. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. *J Clin Psychopharmacol* 2008;**28**:1–4.
35. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011. In: Kleinrock M, editor. Parsippany, NJ, USA: IMS Institute for Healthcare Informatics, 2011.
36. ABBING-KARAHAGOPIAN V, HUERTA C, SOUVEREIN PC et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. *Eur J Clin Pharmacol*. 2014;**70**:849–857.
37. WONG DT, HORNG JS, BYMASTER FP, HAUSER KL, MOLLOY BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. *Life Sci* 1974;**15**:471–479.
38. LÓPEZ-MUÑOZ F, ÁLAMO C. Cuenca El triunfo de la política de diseño racional de psicofármacos: descubrimiento de la fluoxetina. In: *Historia De La Psicofarmacología*, Vol 2, 2.1 edn. Madrid: Panamericana, 2007. p. 1195.
39. SAM. The efficacy of fluoxetine as an antidepressant in the short and long term. *Int Clin Psychopharmacol* 1989;**4**(Suppl. 1):113–119.
40. FAGIUS J, OSTERMAN PO, SIDEN A, WIHOLM BE. Guillain-Barre syndrome following zimeldine treatment. *J Neurol Neurosurg Psychiatry* 1985;**48**:65–69.
41. PINCUS HA, TANIELIAN TL, MARCUS SC et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. *JAMA* 1998;**279**:526–531.
42. SZEGEDY-MASZAK M. The career of a celebrity pill. As Prozac's long reign comes to an end, experts are questioning its legacy. *US News World Rep* 2001;**131**:38–39.
43. SLINGSBY BT. The Prozac boom and its placebo counterpart – a culturally fashioned phenomenon. *Med Sci Monit* 2002;**8**:CR389–CR393.
44. NESTLER EJ. Antidepressant treatments in the 21st century. *Biol Psychiatry* 1998;**44**:526–533.
45. BOOIJ L, VAN DER DOES AJ, RIEDEL WJ. Monoamine depletion in psychiatric and healthy populations: review. *Mol Psychiatry* 2003;**8**:951–973.
46. DELGADO PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. *J Clin Psychiatry* 2006;**67**(Suppl. 4):22–26.
47. MORENO FA, PARKINSON D, PALMER C et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. *Eur Neuropsychopharmacol* 2010;**20**:18–24.

48. HOHMAN LB. A review of one hundred and forty-four cases of affective disorders – after seven years. *Am J Psychiatry* 1937;**94**:303–308.
49. AL-HARBI KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. *Patient Prefer Adherence* 2012;**6**:369–388.
50. KEKS NA, BURROWS GD, COPOLOV DL et al. Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? *Med J Aust* 2007;**186**:142–144.
51. World Health Organization CGF. Improving access and appropriate use of medicines for mental disorders. Geneva: World Health Organization, 2017; Available at <http://apps.who.int/iris/bitstream/10665/254794/1/9789241511421-eng.pdf>. Accessed April 10, 2017.
52. MADDOX VH, GODEFROI EF, PARCELL RF. The synthesis of phencyclidine and other 1-arylcyclohexylamines. *J Med Chem* 1965;**8**:230–235.
53. DOMINO EF. Taming the ketamine tiger. 1965. *Anesthesiology* 2010;**113**:678–684.
54. ANILINE O, PITTS FN JR. Phencyclidine (PCP): a review and perspectives. *Crit Rev Toxicol* 1982;**10**:145–177.
55. DOMINO EF, CHODOFF P, CORSSSEN G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. *Clin Pharmacol Ther* 1965;**6**:279–291.
56. GJESSING J. Ketamine (CI-581) in clinical anaesthesia. *Acta Anaesthesiol Scand* 1968;**12**:15–21.
57. CORSSSEN G, DOMINO EF, BREE RL. Electroencephalographic effects of ketamine anesthesia in children. *Anesth Analg* 1969;**48**:141–147.
58. DUNDEE JW, BOVILL JG, CLARKE RS, PANDIT SK. Problems with ketamine in adults. *Anaesthesia* 1971;**26**:86.
59. PAGE P, MORGAN M, LOH L. Ketamine anaesthesia in paediatric procedures. *Acta Anaesthesiol Scand* 1972;**16**:155–160.
60. SUSSMAN DR. A comparative evaluation of ketamine anesthesia in children and adults. *Anesthesiology* 1974;**40**:459–464.
61. CORAZZA O, ASSI S, SCHIFANO F. From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. *CNS Neurosci Ther* 2013;**19**:454–460.
62. SANACORA G, SCHATZBERG AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? *Neuropsychopharmacology* 2015;**40**:259–267.
63. COLLINGRIDGE GL, WATKINS JC. The NMDA receptor, 2nd edn. New York, NY: Oxford University Press Inc., 1994; 503 pp.
64. ANIS NA, BERRY SC, BURTON NR, LODGE D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. *Br J Pharmacol* 1983;**79**:565–575.
65. HARRISON NL, SIMMONDS MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. *Br J Pharmacol* 1985;**84**:381–391.
66. PERSSON J. Ketamine in pain management. *CNS Neurosci Ther* 2013;**19**:396–402.
67. JOHNSON JW, GLASGOW NG, POVYSHEVA NV. Recent insights into the mode of action of memantine and ketamine. *Curr Opin Pharmacol* 2015;**20**:54–63.
68. DU JARDIN KG, MULLER HK, ELFVING B, DALE E, WEGENER G, SANCHEZ C. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: a critical review. *Prog Neuropsychopharmacol Biol Psychiatry* 2016;**71**:27–38.
69. TRULLAS R, SKOLNICK P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. *Eur J Pharmacol* 1990;**185**:1–10.
70. MOGHADDAM B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. *J Neurochem* 1993;**60**:1650–1657.
71. MOGHADDAM B, ADAMS B, VERMA A, DALY D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *J Neurosci* 1997;**17**:2921–2927.
72. MOGHADDAM B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. *Biol Psychiatry* 2002;**51**:775–787.
73. NOWAK G, TRULLAS R, LAYER RT, SKOLNICK P, PAUL IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. *J Pharmacol Exp Ther* 1993;**265**:1380–1386.
74. SKOLNICK P, LAYER RT, POPIK P, NOWAK G, PAUL IA, TRULLAS R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. *Pharmacopsychiatry* 1996;**29**:23–26.
75. KRYSZAL JH, SANACORA G, DUMAN RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. *Biol Psychiatry* 2013;**73**:1133–1141.
76. ABDALLAH CG, SANACORA G, DUMAN RS, KRYSZAL JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. *Annu Rev Med* 2015;**66**:509–523.
77. ZARATE CA JR., SINGH JB, CARLSON PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry* 2006;**63**:856–864.
78. ZARATE CA JR., BRUTSCHE N, LAJE G et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. *Biol Psychiatry* 2012;**72**:331–338.
79. ZARATE CA JR., BRUTSCHE NE, IBRAHIM L et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biol Psychiatry* 2012;**71**:939–946.
80. LI N, LEE B, LIU RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science* 2010;**329**:959–964.
81. AUTRY AE, ADACHI M, NOSYREVA E et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. *Nature* 2011;**475**:91–95.
82. LI N, LIU RJ, DWYER JM et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. *Biol Psychiatry* 2011;**69**:754–761.
83. PEREIRA VS, ROMANO A, WEGENER G, JOCA SR. Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test. *Psychopharmacology (Berl)* 2015;**232**:2263–2273.
84. FELDER CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. *FASEB J* 1995;**9**:619–625.

85. ALDERTON WK, COOPER CE, KNOWLES RG. Nitric oxide synthases: structure, function and inhibition. *Biochem J* 2001;**357**:593–615.
86. RAHIMIAN R, FAKHFOURI G, EJTEMAEI MEHR S et al. Tropicsteron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats. *Eur J Clin Invest* 2013;**43**:1039–1051.
87. FLORENZANO F, VISCOMI MT, AMADIO S, D'AMBROSI N, VOLONTE C, MOLINARI M. Do ATP and NO interact in the CNS? *Prog Neurobiol* 2008;**84**:40–56.
88. PEREIRA VS, CASAROTTO PC, HIROAKI-SATO VA, SARTIM AG, GUIMARAES FS, JOCA SR. Antidepressant- and anticomulsive-like effects of purinergic receptor blockade: involvement of nitric oxide. *Eur Neuropsychopharmacol* 2013;**23**:1769–1778.
89. GARTHWAITE J, GARTHWAITE G, PALMER RM, MONCADA S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. *Eur J Pharmacol* 1989;**172**:413–416.
90. GUIX FX, URIBESALGO I, COMA M, MUNOZ FJ. The physiology and pathophysiology of nitric oxide in the brain. *Prog Neurobiol* 2005;**76**:126–152.
91. JOCA SR, MOREIRA FA, WEGENER G. Atypical neurotransmitters and the neurobiology of depression. *CNS Neurol Disord Drug Targets* 2015;**14**:1001–1011.
92. CALABRESE V, MANCUSO C, CALVANI M, RIZZARELLI E, BUTTERFIELD DA, STELLA AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. *Nat Rev Neurosci* 2007;**8**:766–775.
93. JEFFERYS D, FUNDER J. Nitric oxide modulates retention of immobility in the forced swimming test in rats. *Eur J Pharmacol* 1996;**295**:131–135.
94. YILDIZ F, ERDEN BF, ULAK G, UTKAN T, GACAR N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. *Psychopharmacology (Berl)* 2000;**149**:41–44.
95. JOCA SR, GUIMARAES FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. *Psychopharmacology (Berl)* 2006;**185**:298–305.
96. ZHOU QG, HU Y, HUA Y et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. *J Neurochem* 2007;**103**:1843–1854.
97. MUTLU O, ULAK G, LAUGERAY A, BELZUNG C. Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. *Pharmacol Biochem Behav* 2009;**92**:82–87.
98. ZHANG GF, WANG N, SHI JY et al. Inhibition of the L-arginine-nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test. *Pharmacol Biochem Behav* 2013;**110**:8–12.
99. LIEBENBERG N, JOCA S, WEGENER G. Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. *Acta Neuropsychiatr* 2015;**27**:90–96.
100. LIU J, MOGHADDAM B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. *J Pharmacol Exp Ther* 1995;**274**:1209–1215.
101. KOIKE H, IJIMA M, CHAKI S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. *Behav Brain Res* 2011;**224**:107–111.
102. MAENG S, ZARATE CA JR., DU J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. *Biol Psychiatry* 2008;**63**:349–352.
103. LI X, TIZZANO JP, GRIFFEY K, CLAY M, LINDSTROM T, SKOLNICK P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). *Neuropharmacology* 2001;**40**:1028–1033.
104. LINDHOLM JS, AUTIO H, VESA L et al. The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf (+/(-) heterozygous null mice. *Neuropharmacology* 2012;**62**:391–397.
105. BARBON A, CARACCILO L, ORLANDI C et al. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. *Neurochem Int* 2011;**59**:896–905.
106. SANACORA G, TRECCANI G, POPOLI M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. *Neuropharmacology* 2012;**62**:63–77.
107. JOURDI H, HSU YT, ZHOU M, QIN Q, BI X, BAUDRY M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. *J Neurosci* 2009;**29**:8688–8697.
108. LEPACK AE, FUCHIKAMI M, DWYER JM, BANASR M, DUMAN RS. BDNF release is required for the behavioral actions of ketamine. *Int J Neuropsychopharmacol* 2014;**18**: pii: pyu033.
109. LIU RJ, LEE FS, LI XY, BAMBICO F, DUMAN RS, AGHAJANIAN GK. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. *Biol Psychiatry* 2012;**71**:996–1005.
110. RICCI V, MARTINOTTI G, GELFO F et al. Chronic ketamine use increases serum levels of brain-derived neurotrophic factor. *Psychopharmacology (Berl)* 2011;**215**:143–148.
111. COSTA-MATTIOLI M, MONTEGGIA LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. *Nat Neurosci* 2013;**16**:1537–1543.
112. YOON SC, SEO MS, KIM SH et al. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. *Neurosci Lett* 2008;**434**:23–28.
113. MAO L, TANG Q, SAMDANI S, LIU Z, WANG JQ. Regulation of MAPK/ERK phosphorylation via ionotropic glutamate receptors in cultured rat striatal neurons. *Eur J Neurosci* 2004;**19**:1207–1216.
114. WANG JQ, TANG Q, PARELKHAR NK et al. Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity. *Mol Neurobiol* 2004;**29**:1–14.
115. NAGAHARA AH, TUSZYNSKI MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. *Nat Rev Drug Discov* 2011;**10**:209–219.
116. GRIMES CA, JOPE RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. *Prog Neurobiol* 2001;**65**:391–426.
117. ZONCU R, EFEBYAN A, SABATINI DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* 2011;**12**:21–35.
118. BEUREL E, SONG L, JOPE RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. *Mol Psychiatry* 2011;**16**:1068–1070.

119. LIU RJ, FUCHIKAMI M, DWYER JM, LEPACK AE, DUMAN RS, AGHAJANIAN GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. *Neuropsychopharmacology* 2013;**38**: 2268–2277.
120. CHIU CT, SCHEUING L, LIU G et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. *Int J Neuropsychopharmacol* 2015;**18**: pii: pyu102.
121. BEUREL E, GRIECO SF, JOPE RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. *Pharmacol Ther* 2015;**148**:114–131.
122. MA XC, DANG YH, JIA M et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. *PLoS One* 2013;**8**:e56053.
123. CADDY C, GIAROLI G, WHITE TP, SHERGILL SS, TRACY DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. *Ther Adv Psychopharmacol* 2014;**4**:75–99.
124. SANACORA G, FRYE MA, McDONALD W et al. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry* 2017;**74**:399–405.
125. SANACORA G, HEIMER H, HARTMAN D et al. Balancing the promise and risks of ketamine treatment for mood disorders. *Neuropsychopharmacology* 2017;**42**:1179–1181.
126. WILKINSON ST, SANACORA G. Considerations on the off-label use of ketamine as a treatment for mood disorders. *JAMA* 2017;**318**:793–794.
127. KISELYCZNYK C, JURY NJ, HALLADAY LR et al. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. *Behav Brain Res* 2015;**287**:89–95.
128. LIMA-OJEDA JM, VOGT MA, PFEIFFER N et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;**45**:28–33.
129. PRESKORN SH, BAKER B, KOLLURI S, MENNITI FS, KRAMS M, LANDEN JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. *J Clin Psychopharmacol* 2008;**28**: 631–637.
130. POLESZAK E, STASIUK W, SZOPA A et al. Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. *Metab Brain Dis* 2016;**31**:803–814.
131. LENER MS, KADRIU B, ZARATE CA JR. Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression. *Drugs* 2017;**77**:381–401.
132. IBRAHIM L, DIAZ GRANADOS N, JOLKOVSKY L et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. *J Clin Psychopharmacol* 2012;**32**:551–557.
133. WEED MR, BOOKBINDER M, POLINO J et al. Negative allosteric modulators selective for the NR2B subtype of the NMDA receptor impair cognition in multiple domains. *Neuropsychopharmacology* 2016;**41**:568–577.
134. SKOLNICK P, POPIK P, TRULLAS R. Glutamate-based antidepressants: 20 years on. *Trends Pharmacol Sci* 2009; **30**:563–569.
135. PAOLETTI P, BELLONE C, ZHOU Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. *Nat Rev Neurosci* 2013;**14**:383–400.
136. RAJAGOPAL L, BURGDORF JS, MOSKAL JR, MELTZER HY. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. *Behav Brain Res* 2016;**299**:105–110.
137. BURGDORF J, ZHANG XL, WEISS C et al. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. *Neurobiol Aging* 2011;**32**:698–706.
138. BURGDORF J, ZHANG XL, NICHOLSON KL et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. *Neuropsychopharmacology* 2013;**38**:729–742.
139. BURCH RM, AMIN KHAN M, HOUCK D et al. NMDA receptor glycine site modulators as therapeutics for depression: rapastinel has antidepressant activity without causing psychotomimetic side effects. *Curr Neuropharmacol* 2016, doi: 10.2174/1570159X14666160202121319.
140. BURGDORF J, ZHANG XL, WEISS C et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. *Neuroscience* 2015; **308**:202–211.
141. LU Y, WANG C, XUE Z et al. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. *Int J Neuropsychopharmacol* 2015;**18**: pii: pyu110.
142. MOSKAL JR, BURGDORF JS, STANTON PK et al. The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. *Curr Neuropharmacol* 2017;**15**:47–56.
143. ZARATE C, DUMAN RS, LIU G, SARTORI S, QUIROZ J, MURCK H. New paradigms for treatment-resistant depression. *Ann N Y Acad Sci* 2013;**1292**:21–31.
144. PRESKORN S, MACALUSO M, MEHRA DO et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. *J Psychiatr Pract* 2015;**21**:140–149.
145. MACHADO-VIEIRA R, HENTER ID, ZARATE CA JR. New targets for rapid antidepressant action. *Prog Neurobiol* 2017;**152**:21–37.
146. LEUNG LY, BAILLIE TA. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. *J Med Chem* 1986;**29**:2396–2399.
147. SALAT K, SIWEK A, STAROWICZ G et al. Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. *Neuropharmacology* 2015;**99**:301–307.
148. ZHAO X, VENKATA SL, MOADDEL R et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. *Br J Clin Pharmacol* 2012;**74**:304–314.

149. ZANOS P, MOADDEL R, MORRIS PJ et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* 2016;**533**:481–486.
150. FARLEY S, APAZOGLOU K, WITKIN JM, GIROS B, TZAVARA ET. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. *Int J Neuropsychopharmacol* 2010;**13**:1207–1218.
151. NATIONS KR, BURSI R, DOGTEROM P et al. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. *Drugs R D* 2012;**12**:127–139.
152. NATIONS KR, DOGTEROM P, BURSI R et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. *J Psychopharmacol* 2012;**26**:1525–1539.
153. DUTTA A, MCKIE S, DEAKIN JF. Ketamine and other potential glutamate antidepressants. *Psychiatry Res* 2015;**225**:1–13.
154. RANTAMAKI T, YALCIN I. Antidepressant drug action – from rapid changes on network function to network rewiring. *Prog Neuropsychopharmacol Biol Psychiatry* 2016;**64**:285–292.